What does ThePharm do?

ThePharm is a pharmacy in Antwerpen. Private Limited, started on 1 January 1968, 1 establishment.

What is the address of ThePharm?

The registered office of ThePharm is located at Lange Stuivenbergstraat 76-78, 2060 Antwerpen.

Is ThePharm still active?

Yes. According to the CBE (30 October 2026) ThePharm is active, legal situation “Normale toestand”, started on 1 January 1968.

Is ThePharm registered on Peppol?

Yes, ThePharm is registered on the Peppol network with ID 0208:0403812681.

What is the enterprise number of ThePharm?

The enterprise number of ThePharm is BE0403812681.

When was ThePharm founded?

ThePharm was founded on 1 January 1968.

Who are the directors of ThePharm?

According to the 2025 annual accounts, the directors of ThePharm are: Vincent De Moor BV.

Is ThePharm a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 January 1968; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did ThePharm make in 2025?

ThePharm posted a profit after taxes of € 112,397 in financial year 2025.

What is the revenue of ThePharm?

As a small company, ThePharm is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 394,908.

How much does an employee at ThePharm earn?

The average wage cost per full-time employee at ThePharm was € 52,700 in 2025: staff costs of € 147,448 for 2.8 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ThePharm have?

According to the 2025 annual accounts, ThePharm has 2.8 full-time equivalents (FTE).

Does ThePharm have a website?

Yes, ThePharm has a website at thepharm.be.

ThePharm (Private Limited) - Antwerpen - BE0403812681

Dossier ThePharm, printed on 30 October 2026 from databakkes.be/en/0403812681/thepharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ThePharm from Antwerpen, company number BE0403812681, closed financial year 2025 with a result of € 112,397 after tax. For that financial year ThePharm recorded a gross margin of € 394,908 and equity of € 268,374. Compared with financial year 2024, the result moved from € 141,998 to € 112,397. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.

What it is worth Healthy

€ 268,374

▼ 7% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 112,397

▼ 21% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 102,327

▼ 33% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 133,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

2.8

▲ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 147,448

▲ 26% vs 2024

€ 52,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,385

▲ 50% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 2 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 153,524

▼ 13% vs 2024

€ 75,611 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.

Owed to suppliers

€ 99,913

▲ 10% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 9,560

▼ 47% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 359,525 Gross margin 2022: € 359,525 First fiscal year in the series	€ 302,370 Gross margin 2023: € 302,370 ▼ 16% vs 2022 (€ 359,525) Unfavourable step	€ 395,241 Gross margin 2024: € 395,241 ▲ 31% vs 2023 (€ 302,370) Favourable step	€ 394,908 Gross margin 2025: € 394,908 Unchanged (€ 395,241) Unfavourable step
Profit after taxes	€ 142,661 Profit after taxes 2022: € 142,661 First fiscal year in the series	€ 91,127 Profit after taxes 2023: € 91,127 ▼ 36% vs 2022 (€ 142,661) Unfavourable step	€ 141,998 Profit after taxes 2024: € 141,998 ▲ 56% vs 2023 (€ 91,127) Favourable step	€ 112,397 Profit after taxes 2025: € 112,397 ▼ 21% vs 2024 (€ 141,998) Unfavourable step	▼ 21%
Equity	€ 420,852 Equity 2022: € 420,852 First fiscal year in the series	€ 291,979 Equity 2023: € 291,979 ▼ 31% vs 2022 (€ 420,852) Unfavourable step	€ 288,977 Equity 2024: € 288,977 ▼ 1% vs 2023 (€ 291,979) Unfavourable step	€ 268,374 Equity 2025: € 268,374 ▼ 7% vs 2024 (€ 288,977) Unfavourable step	▼ 7%
Total debts	€ 349,591 Total debts 2022: € 349,591 First fiscal year in the series	€ 460,102 Total debts 2023: € 460,102 ▲ 32% vs 2022 (€ 349,591) Unfavourable step	€ 371,041 Total debts 2024: € 371,041 ▼ 19% vs 2023 (€ 460,102) Favourable step	€ 321,649 Total debts 2025: € 321,649 ▼ 13% vs 2024 (€ 371,041) Favourable step	▼ 13%
Cash	€ 74,420 Cash 2022: € 74,420 First fiscal year in the series	€ 161,851 Cash 2023: € 161,851 ▲ 117% vs 2022 (€ 74,420) Favourable step	€ 151,976 Cash 2024: € 151,976 ▼ 6% vs 2023 (€ 161,851) Unfavourable step	€ 102,327 Cash 2025: € 102,327 ▼ 33% vs 2024 (€ 151,976) Unfavourable step	▼ 33%
Land & buildings	€ 93,511 Land & buildings 2022: € 93,511 First fiscal year in the series	€ 87,862 Land & buildings 2023: € 87,862 ▼ 6% vs 2022 (€ 93,511) Unchanged	€ 75,666 Land & buildings 2024: € 75,666 ▼ 14% vs 2023 (€ 87,862) Unchanged	€ 70,854 Land & buildings 2025: € 70,854 ▼ 6% vs 2024 (€ 75,666) Unchanged	▼ 6%
Retained profit	€ 181,260 Retained profit 2022: € 181,260 First fiscal year in the series	€ 52,387 Retained profit 2023: € 52,387 ▼ 71% vs 2022 (€ 181,260) Unfavourable step	€ 49,385 Retained profit 2024: € 49,385 ▼ 6% vs 2023 (€ 52,387) Unfavourable step	€ 28,782 Retained profit 2025: € 28,782 ▼ 42% vs 2024 (€ 49,385) Unfavourable step	▼ 42%
Dividend	€ 21,175 Dividend 2022: € 21,175 First fiscal year in the series	€ 220,000 Dividend 2023: € 220,000 ▲ € 198,825 vs 2022 (€ 21,175) Unchanged	€ 145,000 Dividend 2024: € 145,000 ▼ 34% vs 2023 (€ 220,000) Unchanged	€ 133,000 Dividend 2025: € 133,000 ▼ 8% vs 2024 (€ 145,000) Unchanged	▼ 8%
Bank debt	€ 263,266 Bank debt 2022: € 263,266 First fiscal year in the series	€ 227,831 Bank debt 2023: € 227,831 ▼ 13% vs 2022 (€ 263,266) Favourable step	€ 177,068 Bank debt 2024: € 177,068 ▼ 22% vs 2023 (€ 227,831) Favourable step	€ 153,524 Bank debt 2025: € 153,524 ▼ 13% vs 2024 (€ 177,068) Favourable step	▼ 13%
Balance sheet total	€ 777,056 Balance sheet total 2022: € 777,056 First fiscal year in the series	€ 757,781 Balance sheet total 2023: € 757,781 ▼ 2% vs 2022 (€ 777,056) Unchanged	€ 664,806 Balance sheet total 2024: € 664,806 ▼ 12% vs 2023 (€ 757,781) Unchanged	€ 593,897 Balance sheet total 2025: € 593,897 ▼ 11% vs 2024 (€ 664,806) Unchanged	▼ 11%
Employees (FTE)	2.3 Employees (FTE) 2022: 2.3 First fiscal year in the series	2.4 Employees (FTE) 2023: 2.4 ▲ 0.1 vs 2022 (2.3) Unchanged	2.7 Employees (FTE) 2024: 2.7 ▲ 0.3 vs 2023 (2.4) Unchanged	2.8 Employees (FTE) 2025: 2.8 ▲ 0.1 vs 2024 (2.7) Unchanged	▲ 0.1

Key figures of ThePharm, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ThePharm?

What happened at ThePharm in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 30, 2026 New annual accounts for financial year 2025: profit of € 112,397 (▼ 21% vs 2024). Source: NBB ↗
2022 Vincent De Moor BV became a director. NBB
Jun 4, 1996 New establishment in Antwerpen. KBO
Jan 1, 1968 Start of the company according to the CBE. KBO

In short

From € 142,661 profit in 2022 to € 112,397 profit in 2025.

Paid € 173,555 in corporate taxes since 2022.

Best year ever: 2022, with € 142,661 profit.

On average € 141,000 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Vincent De Moor 100%

The stake of Vincent De Moor comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

ThePharm

Behind ThePharm is Vincent De Moor BV. The shares are held by Vincent De Moor (100%).

Directors

According to the 2025 annual accounts

Vincent De Moor BV

Director · represented by De Moor Vincent

since 2022

Shareholders

Vincent De Moor

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Lange Stuivenbergstraat 76-78

2060 Antwerpen

2.001.749.111

Lange Stuivenbergstraat 62

2060 Antwerpen

Active since 4 June 1996

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS thepharm.be

Canonical: https://www.thepharm.be/

About

Technologies

Amazon CloudFrontFont AwesomeGoogle AnalyticsJavaNginxPWAjQueryreCAPTCHA

Hosting & Email

Email provider

Google Workspace

Hosting

AMAZON-AES - Amazon.com, Inc., US

Website info

HTTPS Ja

Languages AR, EN, FR, NL, PS, TR

Features

Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ Load balancing

Details

Company number

0403.812.681

VAT number

BE 0403.812.681

Registered office

Lange Stuivenbergstraat 76-78, 2060 Antwerpen

Names & denominations

ThePharm

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

1 January 1968

Peppol

Active · Active since 1 Jan 2001

Contact

thepharm.be [email protected]

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

ThePharm

Financials

What happened to ThePharm?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions